Adrian J. Haigh Sells 22,223 Shares of Fennec Pharmaceuticals Inc. (TSE:FRX) Stock

Posted by on Apr 24th, 2024

Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report) Senior Officer Adrian J. Haigh sold 22,223 shares of the company’s stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of C$9.32, for a total transaction of C$207,029.47.

Adrian J. Haigh also recently made the following trade(s):

  • On Monday, April 15th, Adrian J. Haigh purchased 22,222 shares of Fennec Pharmaceuticals stock. The stock was purchased at an average price of C$2.31 per share, for a total transaction of C$51,332.82.

Fennec Pharmaceuticals Stock Performance

Shares of Fennec Pharmaceuticals stock opened at C$12.80 on Wednesday. The stock has a market cap of C$346.11 million, a price-to-earnings ratio of -12.55 and a beta of 0.35. The firm’s 50-day moving average is C$13.50 and its 200 day moving average is C$12.74. Fennec Pharmaceuticals Inc. has a 1 year low of C$9.27 and a 1 year high of C$15.43. The company has a debt-to-equity ratio of 881.09, a current ratio of 3.29 and a quick ratio of 10.17.

Fennec Pharmaceuticals (TSE:FRX – Get Free Report) last posted its earnings results on Thursday, March 21st. The biopharmaceutical company reported C($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.02 by C($0.16). The company had revenue of C$13.25 million for the quarter, compared to the consensus estimate of C$12.88 million. Fennec Pharmaceuticals had a negative net margin of 75.50% and a negative return on equity of 1,005.59%. Sell-side analysts anticipate that Fennec Pharmaceuticals Inc. will post 0.4202312 EPS for the current fiscal year.

Fennec Pharmaceuticals Company Profile

(Get Free Report)

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.

Featured Articles

Insider Buying and Selling by Quarter for Fennec Pharmaceuticals (TSE:FRX)

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.